These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20730486)

  • 1. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study.
    Coleman RE; Banks LM; Girgis SI; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Bliss JM; Coombes RC; Kilburn LS
    Breast Cancer Res Treat; 2010 Nov; 124(1):153-61. PubMed ID: 20730486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
    Coleman RE; Banks LM; Girgis SI; Kilburn LS; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Snowdon CF; Hall E; Bliss JM; Coombes RC;
    Lancet Oncol; 2007 Feb; 8(2):119-27. PubMed ID: 17267326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane.
    Gonnelli S; Cadirni A; Caffarelli C; Petrioli R; Montagnani A; Franci MB; Lucani B; Francini G; Nuti R
    Bone; 2007 Jan; 40(1):205-10. PubMed ID: 16904960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy.
    Hadji P; Ziller M; Kieback DG; Dornoff W; Tessen HW; Menschik T; Kuck J; Melchert F; Hasenburg A
    Ann Oncol; 2009 Jul; 20(7):1203-9. PubMed ID: 19218306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
    Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
    Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
    Fallowfield LJ; Bliss JM; Porter LS; Price MH; Snowdon CF; Jones SE; Coombes RC; Hall E
    J Clin Oncol; 2006 Feb; 24(6):910-7. PubMed ID: 16484701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
    Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE;
    J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
    Mieog JS; Morden JP; Bliss JM; Coombes RC; van de Velde CJ;
    Lancet Oncol; 2012 Apr; 13(4):420-32. PubMed ID: 22265698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
    Aihara T; Suemasu K; Takei H; Hozumi Y; Takehara M; Saito T; Ohsumi S; Masuda N; Ohashi Y
    Oncology; 2010; 79(5-6):376-81. PubMed ID: 21430407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
    Hadji P; Ziller M; Kieback DG; Menschik T; Kalder M; Kuck J; Hasenburg A
    Breast; 2009 Jun; 18(3):159-64. PubMed ID: 19364653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
    Love RR; Hutson PR; Havighurst TC; Cleary JF
    Clin Cancer Res; 2005 Feb; 11(4):1500-3. PubMed ID: 15746052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
    Jones S; Stokoe C; Sborov M; Braun M; Ethirajan S; Kutteh L; Pippen J; Patel M; Paul D; Blum JL; Holmes FA; Myron MC; Cantrell J; Hartung NL; Look RM; Di Salle E; Davis JC; Ilegbodu D; Asmar L
    Clin Breast Cancer; 2008 Dec; 8(6):527-32. PubMed ID: 19073509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.
    Kamdem LK; Xi J; Clark BL; Gregory BJ; Kidwell KM; Storniolo AM; Stearns V; Hayes DF; Gersch CL; Rae JM; Henry NL; Hertz DL
    Breast Cancer Res Treat; 2019 Jun; 175(2):297-303. PubMed ID: 30747308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
    Coombes RC; Hall E; Gibson LJ; Paridaens R; Jassem J; Delozier T; Jones SE; Alvarez I; Bertelli G; Ortmann O; Coates AS; Bajetta E; Dodwell D; Coleman RE; Fallowfield LJ; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Stewart A; Stuart N; Snowdon CF; Carpentieri M; Massimini G; Bliss JM; van de Velde C;
    N Engl J Med; 2004 Mar; 350(11):1081-92. PubMed ID: 15014181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.
    Schilder CM; Seynaeve C; Beex LV; Boogerd W; Linn SC; Gundy CM; Huizenga HM; Nortier JW; van de Velde CJ; van Dam FS; Schagen SB
    J Clin Oncol; 2010 Mar; 28(8):1294-300. PubMed ID: 20142601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exemestane for primary prevention of breast cancer in postmenopausal women.
    Zhang Y; Simondsen K; Kolesar JM
    Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study.
    Bliss JM; Kilburn LS; Coleman RE; Forbes JF; Coates AS; Jones SE; Jassem J; Delozier T; Andersen J; Paridaens R; van de Velde CJ; Lønning PE; Morden J; Reise J; Cisar L; Menschik T; Coombes RC
    J Clin Oncol; 2012 Mar; 30(7):709-17. PubMed ID: 22042946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.
    Lønning PE; Geisler J; Krag LE; Erikstein B; Bremnes Y; Hagen AI; Schlichting E; Lien EA; Ofjord ES; Paolini J; Polli A; Massimini G
    J Clin Oncol; 2005 Aug; 23(22):5126-37. PubMed ID: 15983390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
    Oesterreich S; Henry NL; Kidwell KM; Van Poznak CH; Skaar TC; Dantzer J; Li L; Hangartner TN; Peacock M; Nguyen AT; Rae JM; Desta Z; Philips S; Storniolo AM; Stearns V; Hayes DF; Flockhart DA
    Breast Cancer Res Treat; 2015 Nov; 154(2):263-73. PubMed ID: 26536870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of third-generation aromatase inhibitors on bone.
    McCloskey E
    Eur J Cancer; 2006 May; 42(8):1044-51. PubMed ID: 16554149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.